Dr. Shashi Kapadia is an Infectious Diseases physician and health services researcher at Weill Cornell Medicin... Read Bio
The goal of this study is to provide insights for policymakers and public health practitioners seeking to identify settings in which hepatitis C (HCV) treatment capacity may be lacking. Using data from the Health Care Cost Institute (HCCI), the researchers will examine whether HCV treatment that is integrated into primary care has been widely adopted and the impact that may have on the epidemic. They will build on ongoing preliminary analysis using HCCI data and would compare HCV testing and prescription patterns before direct-acting antivirals (DAA) became the standard of care and after DAA became the standard of care, comparing primary care providers and medical specialists. The researchers will also: (1) at the provider level, analyze the change in number and types of providers offering HCV-treatment since the introduction of DAAs; (2) examine the distribution of HCV treatment across providers of different volumes and the change in that distribution since the introduction of DAAs; and (3) at the patient level, compare rates of treatment initiation and completion for patients treated with DAAs at different provider types. Deliverables will include a project work plan and final narrative report. The researchers will also produce paper(s) suitable for publication and present findings at national research meetings and to other stakeholder audiences as appropriate, including policymakers at the federal, state, and local levels and other key stakeholders, as part of the deliverables for this grant.
Grantee Institution: Weill Cornell Medical College
Grant Period: 9/15/19 – 9/14/20